In-vitro Colorectal Cancer Screening Tests Market Report 2026

The in-vitro colorectal cancer screening tests market size has grown strongly in recent years. It will grow from $1.3 billion in 2025 to $1.4 billion in 2026 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to increasing colorectal cancer incidence rates, expansion of population screening programs, growing awareness of early cancer detection, availability of laboratory-based diagnostic infrastructure, improvements in biomarker identification.

The in-vitro colorectal cancer screening tests market size is expected to see strong growth in the next few years. It will grow to $1.82 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing adoption of personalized screening approaches, rising demand for at-home diagnostic solutions, expansion of preventive healthcare initiatives, growing use of AI-assisted result interpretation, increasing focus on cost-effective cancer screening. Major trends in the forecast period include increasing adoption of non-invasive screening tests, rising use of multi-target stool DNA testing, growing integration of blood-based biomarker assays, expansion of home-based sample collection kits, enhanced focus on early detection in asymptomatic populations.

The rising prevalence of colorectal cancer is expected to drive the growth of the in vitro colorectal cancer screening tests market in the coming years. Colorectal cancer is a type of cancer that originates in the colon or rectum, often developing from precancerous polyps. This increasing prevalence is largely attributed to unhealthy lifestyle habits, including poor diet, lack of exercise, and obesity, which raise the risk of polyp formation and cancer development. In vitro colorectal cancer screening tests support early diagnosis by providing non-invasive methods to detect signs of cancer. These tests enhance screening accuracy through advanced biomarker detection, promoting early intervention and improved patient outcomes. For example, in February 2025, the American Cancer Society reported an estimated 154,270 new colorectal cancer cases in the US, up from 152,810 cases in 2024. This trend is driving the expansion of the in vitro colorectal cancer screening tests market.

Leading companies in this market are developing advanced diagnostic solutions, such as multi-target stool DNA tests, to improve early detection accuracy, enhance patient convenience, and reduce colorectal cancer mortality. Multi-target stool DNA tests analyze stool samples for genetic and biochemical markers associated with colorectal cancer and precancerous lesions. For instance, in March 2025, Exact Sciences Corp., a US-based molecular diagnostics company, launched Cologuard Plus, an enhanced at-home colorectal cancer screening test for average-risk adults aged 45 and older. This test uses advanced biomarker technology, offering higher sensitivity and specificity than its predecessor. It employs a refined algorithm to detect DNA mutations and hemoglobin biomarkers, improving detection of colorectal cancer and advanced adenomas. Cologuard Plus provides a non-invasive and convenient screening option, eliminating the need for bowel preparation or dietary restrictions, thereby increasing patient adherence to recommended screening guidelines.

In February 2025, Mainz Biomed N.V., a Germany-based biotech company, partnered with Labor Team W AG to jointly launch ColoAlert. The partnership aims to expand ColoAlert’s availability across Switzerland, leveraging Labor Team W AG’s diagnostic network to enhance early colorectal cancer detection and improve patient outcomes. Labor Team W AG is a Switzerland-based company providing in vitro colorectal cancer screening tests.

Major companies operating in the in-vitro colorectal cancer screening tests market are Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers, Quest Diagnostics Incorporated, Roche Diagnostics International AG, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Natera Inc., BGI Genomics Co. Ltd., NeoGenomics Inc., Guardant Health Inc., CellMax Life Inc., Epigenomics AG, Acuamark Diagnostics Inc., Beacon Biomedical Inc., Mainz Biomed NV, Hologic Inc., Danaher Corporation, Agilent Technologies Inc.

North America was the largest region in the in-vitro colorectal cancer screening tests market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in-vitro colorectal cancer screening tests market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the in-vitro colorectal cancer screening tests market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the in-vitro colorectal cancer screening tests market by increasing costs of imported reagents, assay kits, laboratory instruments, and diagnostic consumables used in stool and blood-based testing. Diagnostic laboratories and hospitals in North America and Europe are most affected due to dependence on imported testing components, while Asia-Pacific faces cost pressure on test kit manufacturing. These tariffs are increasing per-test costs and affecting large-scale screening program budgets. However, they are also encouraging regional manufacturing of diagnostic kits, local sourcing of consumables, and greater investment in domestic laboratory testing capabilities.

The in-vitro colorectal cancer screening tests market research report is one of a series of new reports that provides in-vitro colorectal cancer screening tests market statistics, including in-vitro colorectal cancer screening tests industry global market size, regional shares, competitors with a in-vitro colorectal cancer screening tests market share, detailed in-vitro colorectal cancer screening tests market segments, market trends and opportunities, and any further data you may need to thrive in the in-vitro colorectal cancer screening tests industry. This in-vitro colorectal cancer screening tests market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

In-vitro colorectal cancer screening tests are non-invasive laboratory-based tests that analyze stool or blood samples to detect indications of colorectal cancer or precancerous conditions. These tests facilitate the early detection of colorectal cancer in asymptomatic individuals, enabling timely intervention and reducing cancer-related mortality.

The main types of in-vitro colorectal cancer screening tests include fecal occult blood tests, stool DNA tests, blood biomarker tests, and others. The fecal occult blood test is a non-invasive diagnostic method used to detect hidden blood in the stool, which may signal early colorectal cancer or other gastrointestinal disorders. Various imaging techniques, such as colonoscopy, proctoscopy, computed tomography (CT) scans, ultrasound, magnetic resonance imaging (MRI), and positron emission tomography (PET) scans, support a wide range of applications, including screening, diagnosis, monitoring, risk assessment, and post-treatment surveillance. These tests serve a broad spectrum of end users, including hospitals, diagnostic laboratories, outpatient clinics, home care settings, and research institutions.

The in-vitro colorectal cancer screening tests market consists of revenues earned by entities by providing services such as molecular diagnostic testing, lab sample collection and processing services, risk assessment and genetic counseling services, telehealth-based screening consultations, screening program management for institutions, and electronic health record (EHR) integration services. The market value includes the value of related goods sold by the service provider or included within the service offering. The in vitro colorectal cancer screening tests market also includes sales of sample collection devices, automated screening instruments, sample preservation and transport systems, and digital diagnostic platforms. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.